Evidence map›Paper›PMID 37195913›Full record

ArticleThe Journal of infectious diseases2023

Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Genomic Variation Associated With Breakthrough Infection in Northern California: A Retrospective Cohort Study.

Jacek Skarbinski, Joshua R Nugent, Mariah S Wood, Liyan Liu, Teal Bullick, Jeffrey M Schapiro, Phacharee Arunleung, Christina Morales, Laura B Amsden, Crystal A Hsiao and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Jacek SkarbinskiDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.ORCID 0000-0003-1630-5733
Joshua R NugentDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Mariah S WoodDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Liyan LiuDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Teal BullickViral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, California, USA.
Jeffrey M SchapiroThe Permanente Medical Group, Kaiser Permanente Northern California, Oakland, California, USA.
Phacharee ArunleungViral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, California, USA.
Christina MoralesViral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, California, USA.
Laura B AmsdenDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Crystal A HsiaoDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Debra A WadfordViral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, California, USA.
Shua J ChaiCareer Epidemiology Field Officer, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Arthur ReingoldSchool of Public Health, University of California, Berkeley, Berkeley, California, USA.
Stacia K WymanInnovative Genomics Institute, University of California, Berkeley, Berkeley, California, USA.
Kaiser Permanente · USCalifornia Department of Public Health · USBerkeley Public Health Division · USCenters for Disease Control and Prevention · USInnovative Genomics Institute · US

Funding

SARS-CoV-2 Serological Antibody Testing for Disease Surveillance and Clinical UseU01CA260584 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI SKARBINSKI, JACEK · 2020 to 2024
$3.3M
ACL HHS U01CK000539NCEZID CDC HHS U01 CK000539NCI NIH HHS U01 CA260584
6 · The paper itself

Abstract

backgroundThe association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic variation and breakthrough infection is not well defined among persons with Delta variant SARS-CoV-2 infection.

methodsIn a retrospective cohort, we assessed whether individual nonlineage defining mutations and overall genomic variation (including low-frequency alleles) were associated with breakthrough infection, defined as SARS-CoV-2 infection after coronavirus disease 2019 primary vaccine series. We identified all nonsynonymous single-nucleotide polymorphisms, insertions, and deletions in SARS-CoV-2 genomes with ≥5% allelic frequency and population frequency of ≥5% and ≤95%. Using Poisson regression, we assessed the association with breakthrough infection for each individual mutation and a viral genomic risk score.

resultsThirty-six mutations met our inclusion criteria. Among 12 744 persons infected with Delta variant SARS-CoV-2, 5949 (47%) were vaccinated and 6795 (53%) were unvaccinated. Viruses with a viral genomic risk score in the highest quintile were 9% more likely to be associated with breakthrough infection than viruses in the lowest quintile, but including the risk score improved overall predictive model performance (measured by C statistic) by only +0.0006.

conclusionsGenomic variation within SARS-CoV-2 Delta variant was weakly associated with breakthrough infection, but several potential nonlineage defining mutations were identified that might contribute to immune evasion by SARS-CoV-2.

Indexed as

COVID-19SARS-CoV-2Breakthrough InfectionsCaliforniaCOVID-19 VaccinesGenomicsHumansRetrospective StudiesCOVID-19 Vaccinesgenomic variationimmune evasionSARS-CoV-2

Identifiers

PMID37195913
PMCPMC11009495
OpenAlexW4376870778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.